Sohail R, Khan Z, Hussain Shah H, Orciuolo J, Fan D, Patel R, Estrada Zamudio A, Chaudhry S, Khattak R, Suresh MG. Proton pump inhibitors for gastrointestinal bleeding prevention after percutaneous coronary intervention: Comparing evidence in dual antiplatelet therapy. World J Gastroenterol 2026; 32(48): 120932 [DOI: 10.3748/wjg.120932]
Corresponding Author of This Article
Rohab Sohail, MD, Doctor, Department of Internal Medicine, Bayhealth Medical Center, 640 South State Street, Dover, DE 19904, United States. rohabsohail98@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 28, 2026; 32(48): 120932 Published online Dec 28, 2026. doi: 10.3748/wjg.120932
Proton pump inhibitors for gastrointestinal bleeding prevention after percutaneous coronary intervention: Comparing evidence in dual antiplatelet therapy
Rohab Sohail, Zaraq Khan, Haider Hussain Shah, Jason Orciuolo, Dwight Fan, Rohan Patel, Ana Estrada Zamudio, Shahryar Chaudhry, Ridda Khattak, Mithil Gowda Suresh
Rohab Sohail, Jason Orciuolo, Dwight Fan, Rohan Patel, Ana Estrada Zamudio, Shahryar Chaudhry, Ridda Khattak, Department of Internal Medicine, Bayhealth Medical Center, Dover, DE 19904, United States
Zaraq Khan, Department of Internal Medicine, Indiana University School of Medicine, Southwest Internal Medicine Residency Program, Evansville, IN 46202, United States
Haider Hussain Shah, Department of Medicine, Bayhealth Hospital, Kent Campus, Dover, DE 19901, United States
Mithil Gowda Suresh, Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA 01608, United States
Author contributions: Sohail R, Khan Z, and Hussain Shah H formulated the study design, performed analysis and drafted tables; Khattak R, Orciuolo J, Chaudhry S, and Estrada Zamudio A were involved in writing manuscript; Suresh MG reviewed the final draft and supervised the project; Sohail R, Khan Z, Hussain Shah H, Orciuolo J, Fan D, Patel R, Estrada Zamudio A, Chaudhry S, Khattak R, Suresh MG approval the final manuscript.
AI contribution statement: AI technologies were used in writing process to improve the readability of the manuscript. No AI technologies were involved in the generation of results or formation of figures or tables.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Rohab Sohail, MD, Doctor, Department of Internal Medicine, Bayhealth Medical Center, 640 South State Street, Dover, DE 19904, United States. rohabsohail98@gmail.com
Received: March 12, 2026 Revised: July 26, 2026 Accepted: October 20, 2026 Published online: December 28, 2026 Processing time: 237 Days and 1.4 Hours
Core Tip
Core Tip: Proton pump inhibitor (PPI) co-therapy remains an effective strategy for preventing upper gastrointestinal (GI) bleeding in patients receiving dual antiplatelet therapy after percutaneous coronary intervention. This systematic review and meta-analysis separately evaluated randomized trials and observational studies, demonstrating consistent protection against upper GI bleeding while highlighting differences in effect estimates across study designs. Observational findings regarding lower GI bleeding, major bleeding, and all-cause mortality should be interpreted cautiously because of lower certainty and potential confounding. These findings support current guideline recommendations for PPI use while emphasizing the need for further high-quality studies to clarify long-term safety and comparative efficacy among individual PPIs.
